2Kleber FX,Wensel R.Current guidelines for the treatment of congestive heart failure[J].Drug,1996,51:89—91.
3Forker AD.Cardiologist S perspective on evolving concepts in the management of congestive heart failure[J].J Clin Pharmacol,1996,36:973—975.
4Waagstein F, Hjalmarson A,Varnauskkas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy [J] Br Heart J, 1975,37 : 1002-1005.
5Swedber K,Waagestein F,Hjialmarson A, et al. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade[J]. Lancet, 1979,1 :1374-1376.
6Swedberg K, Waagstein F, Hjalmarson A, et al. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomypathy[J]. Br Heart J, 1980,44:134-136.
7Swedberg K, Hjalmarson A, Waagstein F, et al. Beneficial effects of long-term beta-receptor blockade [J]. Br Heart J, 1980,44:117-119.
8Waagestein F, Bristow MR, Swedberg K, et al. Beneficial effct of metoprolol in idiopathic dilated cardiomyopathy[J]. Lancet, 1993,342:1441-1446.
9Hjalmarson A, Goldstein S, Fagerberg B,et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) [J ]. JAMA, 2000,283 : 1295-1302.
10CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure:the Cardiac Insufficiency Bisoprolol Study(CIBIS)[J]. Circulation, 1994,90 : 1765-1773.
